Sorafenib generally does not require genetic testing.
Sorafenib is an antitumor drug with dual antitumor effects, which can directly inhibit tumor cell proliferation by blocking the cell signaling pathway mediated by RAF/MEK/ERK, and indirectly inhibit tumor cell growth by blocking tumor neovascularization through the inhibition of VEGFR and platelet-derived growth factor (PDGF) receptors.
The drug is clinically used for the treatment of inoperable advanced renal cell carcinoma and primary hepatocellular carcinoma with distant metastasis. Since the target of action of Sorafenib is not a specific gene mutation, genetic testing is generally not required before administration.
There may be an increased chance of bleeding with sorafenib; severe bleeding is uncommon. In the event that bleeding requires treatment, it is recommended that permanent discontinuation of the drug be considered. Permanent discontinuation may be necessary in patients with severe skin toxicity and persistent reactions. The drug is contraindicated in patients with severe hypersensitivity to the drug.
When taking Sorafenib, patients are advised to do so under the supervision of a physician and not blindly self-administer the drug to avoid medication risks.